All Stories

  1. Towards optimising and standardising donor screening for faecal microbiota transplantion
  2. Microbiota transplants: the concept of ‘microbiome mismatching’ explored
  3. A practical approach to nutrition in people with cirrhosis
  4. A large-scale comparison of clinical outcomes to IBD therapies in White and South Asian ethnicities
  5. GI highlights from the literature
  6. The impact of three distinct probiotic supplements on the gut microbiota and its metabolites in healthy adults
  7. The emerging role of the gut microbiota in vaccination responses
  8. Exploring the differential impact of steatotic liver disease phenotypes upon clinical outcomes
  9. Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service
  10. Deciphering the microbiome–metabolome landscape of an inflammatory bowel disease inception cohort
  11. Correction to: Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy
  12. Vancomycin-resistant enterococci utilise antibiotic-enriched nutrients for intestinal colonisation
  13. GI highlights from the literature
  14. Risk factors of metabolic dysfunction-associated steatotic liver disease in a cohort of patients with chronic hepatitis B
  15. Non-antimicrobial therapies for recurrent urinary tract infection in women: is there a place for faecal microbiota transfer?
  16. Metabolic-associated steatotic liver disease (MASLD): how I evolved my approach to diagnosis and staging
  17. The relationships between MASLD, extrahepatic multimorbidity and all-cause mortality in UK Biobank cohort
  18. Interplay of constipation, intestinal barrier dysfunction and fungal exposome in aetiopathogenesis of Parkinson’s disease: hypothesis with supportive data
  19. 127: A LARGE-SCALE COMPARATIVE ANALYSIS OF ETHNIC DIFFERENCES IN CLINICAL RESPONSE TO IBD THERAPIES IN THE UK.
  20. Clostridioides difficile: Treating Sustained Antibiotic Responders With Fecal Microbiota Transplantation Does Not Improve Efficacy
  21. Deciphering the microbiome–metabolome landscape of an inflammatory bowel disease inception cohort
  22. The relationships between MASLD, extrahepatic multimorbidity and all-cause mortality in UK Biobank cohort
  23. GI highlights from the literature
  24. FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial
  25. P0787 A large-scale comparison of clinical response to IBD therapies in white and non-white ethnicities
  26. Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures
  27. Vancomycin-resistantEnterococcuscolonise the antibiotic-treated intestine by occupying distinct nutrient- and metabolite-defined intestinal niches
  28. Diverse phenotypes, consistent treatment: a study of 30,997 South Asian and White IBD patients using the UK IBD BioResource
  29. International consensus statement on microbiome testing in clinical practice
  30. IntestinalMicrobiota Transplant Prior toAllogeneicStem CellTransplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial
  31. GI highlights from the literature
  32. Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome
  33. Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST): A Multi-Center Randomized Double-Blinded Placebo-Controlled Phase IIa Trial
  34. New agonists of the incretin/glucagon system for the treatment of metabolic dysfunction-associated steatohepatitis
  35. Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community
  36. Preface to Special Edition: Microbiome, Inflammation and Cancer
  37. GI highlights from the literature
  38. 3D printed rectal swabs for assessing the gut microbiome, metabolome and inflammation
  39. Inflammation, oxidative stress and gut microbiome perturbation: A narrative review of mechanisms and treatment of the alcohol hangover
  40. Alcohol-Associated liver disease: Emerging therapeutic strategies
  41. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
  42. FRI-215-YI MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease
  43. FRI-286 Muscle function and walking time are associated with better quality of life in MASLD patients
  44. OS-070 Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling
  45. THU-317 Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression
  46. WED-546 Evidence of gut microbiome differences in post-menopausal females with metabolic dysfunction-associated liver disease compared to pre-menopausal females and males
  47. P126 Gut microbiota composition and functionality in a thiopurine-naïve cohort of inflammatory bowel disease (IBD) can differentiate between clinical outcomes
  48. P61 Ethnic differences in ulcerative colitis: a study of 15,053 South Asian and white patients using the UK IBD bioresource
  49. Decision
  50. The Role of Fecal Microbiota Transplantation in the Treatment of Obesity, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease
  51. Authors' reply to letter: He who controls Clostridia and Bacteroidia controls the gut microbiome: The concept of targeted probiotics to restore the balance of keystone taxa in irritable bowel syndrome
  52. GI highlights from the literature
  53. Mo1870 CONSISTENT APPROACH TO IBD TREATMENT ACROSS SOUTH ASIAN AND WHITE ETHNICITIES IN THE UK DESPITE PHENOTYPIC VARIATIONS: A STUDY OF 33,157 PATIENTS USING THE IBD BIORESOURCE
  54. Sa1871 THE COMPOSITION AND FUNCTION OF THE GUT MICROBIOTA IN A TREATMENT NAIVE INCEPTION COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) CAN ACCURATELY DIFFERENTIATE IBD PHENOTYPE.
  55. Sa1889 3D PRINTED RECTAL SWABS FOR ASSESSING THE GUT MICROBIOME, METABOLOME, AND INFLAMMATION
  56. Sa1927 ANTIBIOTIC TREATMENT PROMOTES THE INTESTINAL COLONISATION OF VANCOMYCIN-RESISTANT ENTEROCOCCUS BY KILLING MEMBERS OF THE GUT MICROBIOTA AND DECREASING NUTRIENT COMPETITION
  57. Su1558 GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS REDUCE HEPATIC FAT CONTEXT INDEPENDENT OF THE WEIGHT LOSS IN DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE
  58. The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond
  59. The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridioides difficileinfection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society...
  60. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS...
  61. Lyophilized fecal microbiome transfer for primary Clostridioides difficile infection: a multicenter randomized controlled trial (DONATE Study)
  62. Overview of the second edition of the joint British Society of Gastroenterology and Healthcare Infection Society faecal microbiota transplant guidelines, 2024
  63. The beneficial hepatic effects of glucagon‐like peptide 1 receptor agonists in patients with diabetes and metabolic dysfunction‐associated steatotic liver disease are independent of weight loss
  64. GI highlights from the literature
  65. A double‐blind, randomized, placebo‐controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females
  66. Disruption of gut barrier integrity and host–microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus
  67. Dynamics of inflammation-associated plasma proteins following faecal microbiota transplantation in patients with psoriatic arthritis and healthy controls: exploratory findings from the FLORA trial
  68. OP07 Consistent IBD treatment approaches across South Asian and White ethnicities despite phenotypic variations: a study of 33,157 patients using the IBD BioResource
  69. P1209 Baseline gut microbiota composition and function reflect response to 5-ASA treatment in Ulcerative Colitis
  70. Risk Factors for Liver Cancer and Chronic Liver Disease-related Death: Are Sugar Substitutes Better Than the Real Thing?
  71. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
  72. Liver sinusoidal cells in the diagnosis and treatment of liver diseases: Role of hepatic stellate cells
  73. Evaluating Protocols for Reproducible Targeted Metabolomics by NMR
  74. Pharmacotherapy in Managing Alcohol-Use Disorder
  75. The role of faecal microbiota transplantation in chronic noncommunicable disorders
  76. GI highlights from the literature
  77. Gut microbiota and immunotherapy of renal cell carcinoma
  78. Author Correction: Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
  79. THU642 Progression To Cirrhosis And All-cause Mortality Are Increased In Postmenopausal Women With NAFLD
  80. Alcohol Minimum Unit Pricing Reduces Alcohol-Specific Hospitalizations and Deaths
  81. Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA<...
  82. A prospective study on the prevalence of MASLD in people with type‐2 diabetes in the community. Cost effectiveness of screening strategies
  83. O6 The beneficial hepatic-effect of glucagon-like peptide 1 receptor agonists in diabetic patients with non-alcoholic fatty liver disease
  84. P18 A 5 sit-to-stand test may identify NAFLD patients at higher risk for worse clinical outcomes
  85. P26 Exploring the association between quality of life, diet, physical activity, and binge eating disorder in NAFLD patients in a tertiary centre of care
  86. Antibiotics promote intestinal growth of carbapenem-resistant Enterobacteriaceae by enriching nutrients and depleting microbial metabolites
  87. GI highlights from the literature
  88. Faecal microbiota transplant restores intestinal barrier function and augments ammonia metabolism in patients with cirrhosis: a randomised single-blind placebo-controlled trial
  89. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
  90. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
  91. Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease
  92. P79 COVID-19 vaccine-induced antibody response is associated with oral microbiota composition in patients with inflammatory bowel disease, cirrhosis, and liver transplantation
  93. P325 Colonoscopy surveillance in primary sclerosing cholangitis patients during the COVID-19 pandemic – a tertiary centre experience
  94. Faecal microbiota transplant restores gut barrier function and augments ammonia metabolism in patients with advanced cirrhosis: a randomised single-blind placebo-controlled trial
  95. Investigating the correlation of a poly-metabolic risk score to clinical features in non-alcoholic fatty liver disease patients throughout a faecal microbiota transplant clinical trial
  96. Metabolic profile reflects stages of fibrosis in patients with non-alcoholic fatty liver disease
  97. Poor performance at five times sit-to-stand test, but not at handgrip test, is related to significant liver fibrosis and correlates with major cardiovascular events in non-alcoholic fatty liver disease patients
  98. Short-chain fatty and carboxylic acid changes associated with fecal microbiota transplant communally influence microglial inflammation
  99. The Impact of Proportional Dietary Carbohydrate and Fat Content on Type 2 Diabetes and NAFLD
  100. POS0423 PLASMA METABOLOMIC PROFILES OF PATIENTS WITH ACTIVE PERIPHERAL PSORIATIC ARTHRITIS CAN DIFFERENTIATE TREATMENT RESPONDERS FROM FAILURES: EXPLORATORY FINDINGS FROM THE FLORA TRIAL
  101. A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease
  102. Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
  103. GI highlights from the literature
  104. Increased risk of cirrhosis in post-menopausal women with NAFLD
  105. Tu1866 SALIVARY MICROBIOTA COMPOSITION IS ASSOCIATED WITH ANTIBODY RESPONSE FOLLOWING COVID-19 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE, CIRRHOSIS AND LIVER TRANSPLANTATION
  106. Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
  107. Screening for NAFLD—Current Knowledge and Challenges
  108. The gastrointestinal status of healthy adults: a post hoc assessment of the impact of three distinct probiotics
  109. GI highlights from the literature
  110. Antibiotics promote intestinal growth of carbapenem-resistantEnterobacteriaceaeby enriching nutrients and depleting microbial metabolites
  111. Prospective evaluation of screening strategies for NAFLD in people with type-2 diabetes mellitus in the community
  112. Metabolic Profile Reflects Stages of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease
  113. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
  114. Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition
  115. GI highlights from the literature
  116. Faecal metabolite deficit, gut inflammation and diet in Parkinson's disease: Integrative analysis indicates inflammatory response syndrome
  117. Editorial: the acid test—can bile acids predict recurrence of Clostridioides difficile infection? Authors' reply
  118. Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans
  119. GI highlights from the literature
  120. 627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy
  121. 614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients
  122. Minimising the risk of monkeypox virus transmission during faecal microbiota transplantation: recommendations from a European expert panel
  123. Assessing the clinical value of faecal bile acid profiling to predict recurrence in primary Clostridioides difficile infection
  124. Clinical and cost-effectiveness analysis of community-based screening strategies for non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus
  125. UEG Week 2022 Poster Presentations
  126. Polymorphic microbes: a new emerging hallmark of cancer
  127. New insights into host‐microbiome crosstalk in psoriatic skin
  128. Recent Findings in the Gut-Liver Axis and Associated Disease Therapy
  129. GI highlights from the literature
  130. Further Insights Into the Impact of Bariatric Surgery on the Progression of Nonalcoholic Fatty Liver Disease
  131. Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review
  132. A study evaluating outcomes of a virtual specialist liver cirrhosis clinic
  133. Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus
  134. Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls
  135. Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD
  136. Humoral and cellular immune responses to SARS-CoV-2 vaccination across multiple vaccine platforms and liver disease types: an EASL registry multicentre prospective cohort study
  137. Intestinal microbiota transplantation: do not forget the metabolites
  138. Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases
  139. Fecal bile acid profiles predict recurrence in patients with primary Clostridioides difficile infection
  140. GI highlights from the literature
  141. P2 COVID-19 vaccination response in immunosuppressed patients with IBD is associated with altered gut microbiota function
  142. The gut microbiota and metabolome is associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
  143. Identifying transient and stable bacteria- metabolite interactions from longitudinal multi-omics data
  144. Effects of bowel preparation on intestinal bacterial associated urine and faecal metabolites and the associated faecal microbiome
  145. 643: CLINICAL AND ECONOMICAL EVALUATION OF COMMUNITY-BASED PREVENTATIVE SCREENING STRATEGIES FOR NON-ALCOHOLIC FATTY LIVER DISEASE
  146. 681: FACTORS ASSOCIATED WITH INCREASED GUT PERMEABILITY AND SEVERITY OF LIVER DISEASE IN DIABETIC PATIENTS WITH NAFLD
  147. 894: RELATIVE CHANGE OF ENTEROCOCCUS FAECIUM, SELECTED COMMENSAL BACTERIA AND CYTOKINES ARE SEEN IN PATIENTS COLONIZED WITH MULTIDRUG-RESISTANT ORGANISMS WHO UNDERGO INTESTINAL MICROBIOTA TRANSPLANTATION.
  148. Mo1589: IMPACT ON GUT MICROBIAL METABOLITES FROM A 6-MONTH DOUBLEBLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL OF FECAL MICROBIOTA TRANSPLANTATION FOR ACTIVE PERIPHERAL PSORIATIC ARTHRITIS
  149. Sa1657: NEW LINKS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOME SUGGEST A STRONGER ROLE OF THE GUT-JOINT AXIS
  150. Su1601: INTESTINAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIODIOIDES DIFFICILE INFECTION IS ASSOCIATED WITH RESTORATION OF MICROBIAL ARYLSULFATASES AND SULFATIDE DEGRADATION
  151. Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION
  152. Tu1312: EXAMINING THE CORRELATION OF HISTOLOGICAL FEATURES OF NAFLD WITH A POLYMETABOLIC RISK SCORE FOR PREDICTING PATIENTS WITH NAFLD
  153. Impact of gastrointestinal surgery upon the gut microbiome: A systematic review
  154. How to adapt an intestinal microbiota transplantation programme to reduce the risk of invasive multidrug-resistant infection
  155. GI highlights from the literature
  156. The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
  157. Rectal swabs as a viable alternative to faecal sampling for the analysis of gut microbiota functionality and composition
  158. The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease
  159. The potential of fecal microbiota transplantation in oncology
  160. Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?
  161. GI highlights from the literature
  162. A Multi-Factorial Observational Study on Sequential Fecal Microbiota Transplant in Patients with Medically Refractory Clostridioides difficile Infection
  163. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease
  164. Clostridioides difficile: innovations in target discovery and potential for therapeutic success
  165. Outcomes of postmenopausal women with non-alcoholic fatty liver disease (NAFLD)
  166. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series
  167. GI highlights from the literature
  168. The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey
  169. Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use
  170. Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation
  171. GI highlights from the literature
  172. Binge‐eating disorder is associated with an unfavorable body mass composition in patients with non‐alcoholic fatty liver disease
  173. Multiomics Profiling Reveals Signatures of Dysmetabolism in Urban Populations in Central India
  174. Rapid resolution of COVID-19 after faecal microbiota transplantation
  175. GI highlights from the literature
  176. 739 DAILY PROBIOTIC USE IS ASSOCIATED WITH A REDUCED RATE OF UPPER RESPIRATORY TRACT SYMPTOMS IN OVERWEIGHT AND OBESE PEOPLE
  177. 811 FECAL MICROBIOTA TRANSPLANT PRIOR TO ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN PATIENTS COLONIZED WITH MULTI-DRUG RESISTANT ORGANISMS IS ASSOCIATED WITH IMPROVED SURVIVAL
  178. Fr571 A DISTINCTIVE SIGNATURE OF FECAL BILE ACIDS AND OTHER NOVEL METABOLITES ACCOMPANYING RECURRENCE AFTER PRIMARY CLOSTRIDIOIDES DIFFICILE INFECTION
  179. Fr573 ASSOCIATION BETWEEN NOVEL METABOLOMIC BIOMARKERS AND C.DIFFICILE RECURRENCE
  180. Sa022 A HIGH-FIBER LOW-FAT DIET INCREASES FECAL LEVELS OF LITHOCHOLIC ACID DERIVATIVE 3-KETOCHOLANIC ACID
  181. Su541 RECTAL SWABS AS A VIABLE ALTERNATIVE TO FECAL SAMPLING FOR THE ANALYSIS OF GUT MICROBIOME FUNCTIONALITY AS WELL AS COMPOSITION
  182. SARS-CoV-2 vaccines and donor recruitment for FMT
  183. Romanian National Guideline on Translating Fecal Microbiota Transplantation Applications related to Clostridioides difficile Infections into the Local Clinical Practice
  184. Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections
  185. GI highlights from the literature
  186. Fecal Microbiota Transplantation: The Evolving Risk Landscape
  187. Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity
  188. Daily supplementation with the Lab4P probiotic consortium induces significant weight loss in overweight adults
  189. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?
  190. NAFLD: Time to apply quantitation in liver biopsies as endpoints in clinical trials
  191. The contribution of bile acid metabolism to the pathogenesis of Clostridioides difficile infection
  192. Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial
  193. P307 FMT-associated alterations in the TCR repertoire of patients with severe or fulminant clostridioides difficile infection
  194. Non-Alcoholic Fatty Liver Disease and Vascular Disease
  195. Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection
  196. The 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (O010-O173)
  197. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis
  198. GI highlights from the literature
  199. Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection
  200. Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection
  201. A Guide to the Gut Microbiome and its Relevance to Critical Care
  202. Letter: intestinal microbiota transfer—updating the nomenclature to increase acceptability
  203. Reply to Woodworth, et al.
  204. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19
  205. Abstract Supplement ACR Convergence 2020
  206. S0650 Fecal Microbiota Transplantation Decolonizes C. difficile in Patients With Inflammatory Bowel Disease and Concomitant C. difficile Infection
  207. Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites
  208. Intestinal microbiome transfer, a novel therapeutic strategy for COVID-19 induced hyperinflammation?
  209. Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders
  210. High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease
  211. Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis
  212. Disease Prevention Not Decolonization: A Model for Fecal Microbiota Transplantation in Patients Colonized With Multidrug-resistant Organisms
  213. Letter: faecal microbiota transplantation for IBS
  214. Letter: liver disease and COVID‐19—not the perfect storm
  215. GI highlights from the literature
  216. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic
  217. Correction to Lancet Gastroenterol Hepatol 2020; 5: 430–31
  218. 1144 FECAL MICROBIOTA TRANSPLANT FOR MULTI-DRUG RESISTANT ORGANISMS: IMPROVED CLINICAL OUTCOMES BEYOND INTESTINAL DECOLONISATION
  219. 121 ULCERATIVE COLITIS PATIENTS ACHEIVE MORE ROBUST ENGRAFTMENT COMPARED TO PATIENTS WITH CROHN'S DISEASE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR THE TREATMENT OF RECURRENT C. DIFFICLE INFECTION
  220. 644 IDENTIFICATION OF NOVEL CHANGES IN MICROBIALLY-DERIVED METABOLITES AFTER FECAL MICROBIOTA TRANSPLANT FOR RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION
  221. Mo1939 TEMPORAL MODULATION OF TCR REPERTOIRE FOLLOWING SEQUENTIAL FMT TREATMENT IN PATIENTS WITH SEVERE OR FULMINANT CLOSTRIDIOIDES DIFFICILE INFECTION
  222. Sa1923 IDENTIFICATION OF NEW ASSOCIATIONS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOTA, A PHENOMIC STUDY
  223. Tu1909 IMPACT OF FECAL MICROBIOTA TRANSPLANTATION ON PREVENTION OF METABOLIC SYNDROME AMONG PATIENTS WITH OBESITY
  224. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel
  225. Identifying the factors influencing outcome in probiotic studies in overweight and obese patients: host or microbiome?
  226. GI highlights from the literature
  227. Effects of Fecal Microbiota Transplantation With Oral Capsules in Obese Patients
  228. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being
  229. GI highlights from the literature
  230. Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy
  231. The gut microbiome: what every gastroenterologist needs to know
  232. Case-control study of recurrent Extended-Spectrum Beta Lactamase Enterobacteriaceae Urinary Tract Infections (ESBL UTIs): the management challenges
  233. Cohort study of Faecal Microbiota Transplantation for patient’s colonised with MDROs - successful prevention of invasive disease despite low decolonisation rates
  234. Faculty Opinions recommendation of Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection.
  235. Faecal microbiota transplantations and urinary tract infections – Authors' reply
  236. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease
  237. P844 Higher proportions of genera and species in the Firmicutes phylum are associated with a healthy pouch compared with patients with chronic pouchitis
  238. The gut microbiome: an under-recognised contributor to the COVID-19 pandemic?
  239. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
  240. Antibiotic therapy and outcome from immune-checkpoint inhibitors
  241. Letter: role of mean platelet volume levels in the prediction of major acute cardiovascular events in patients with non‐alcoholic fatty liver disease—authors' reply
  242. 185 Evaluating Dynamics of Bile Acid Metabolism to Predict Recurrence of Clostridioides difficile Infection
  243. 837 Short Chain Fatty Acid Profiles Are Altered by Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease and Recurrent Clostridioides difficile Infection
  244. Posters (Abstracts 289–2348)
  245. Guidelines - Stool banking for faecal microbiota transplantation in clinical practice
  246. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications
  247. Faecal microbiota transplant for eradication of multidrug-resistant Enterobacteriaceae: a lesson in applying best practice? Re: ‘A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enter...
  248. BAUS 2019 Abstract Book
  249. Recurrent bacteraemia following variceal haemorrhage
  250. In search of stool donors: a multicenter study of prior knowledge, perceptions, motivators, and deterrents among potential donors for fecal microbiota transplantation
  251. 621 – Fecal Microbiota Transplantation for the Treatment of Obesity: A Randomized, Placebo-Controlled Pilot Trial
  252. 7 – The Icon Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation
  253. Mo1953 – Growth Inhibition of Clostridioides Difficile by Short and Medium Chain Fatty Acids
  254. Sa1924 – Effect of Short Chain Fatty Acids on Gut-Brain Axis Using a Microglial Cell Model
  255. MP71-15 PREVALENCE OF RECURRENT EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) URINARY TRACT INFECTIONS (UTIS) IN PATIENTS WITHIN A UROLOGY SERVICE. INTRODUCING THE CONCEPT OF FAECAL MICROBIOTA TRANSPLANTATION (FMT) AS A TREATMENT MODALITY
  256. PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis
  257. SAT-294-Automated quantitation of steatosis, inflammation, ballooning and fibrosis using machine learning in routine histological images of liver biopsies of patients with NAFLD
  258. THU-306-Liver function tests in NAFLD: Changes in upper normal limits, does it really matter?
  259. THU-331-Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease: The importance of an elevated mean platelet volume
  260. Editorial: importance of an elevated mean platelet volume for prediction of major adverse cardiovascular events in non‐alcoholic fatty liver disease – authors’ reply
  261. Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non‐alcoholic fatty liver disease; the importance of an elevated mean platelet volume
  262. Prevalence of recurrent extended-spectrum beta-lactamase (ESBL) urinary tract infections (UTIs) in patients within a urology service. Introducing the concept of faecal Microbiota transplantation (FMT) as a treatment modality
  263. Current and future targets for faecal microbiota transplantation
  264. Current and future pharmacological therapies for managing cirrhosis and its complications
  265. Liver Biopsy
  266. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection
  267. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial
  268. The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease
  269. Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease
  270. 1171. Impact on Mortality, Length of Stay, and Antibiotic Use in Allogenic and Autologous Stem Cell Transplant Patients Colonized With Carbapenemase-Producing Enterobacteriaceae
  271. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota
  272. Non-alcoholic fatty liver disease and cardiovascular risk: an update
  273. Bile Acid Profiles are Not Altered by Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis: Category Award (Liver): Presidential Poster Award
  274. Introduction to the joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) faecal microbiota transplant guidelines
  275. Functional microbiomics: Evaluation of gut microbiota-bile acid metabolism interactions in health and disease
  276. Posters (Abstracts 301–2389)
  277. Publisher’s Note: Poster Abstract
  278. Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in the bile acid-farnesoid X receptor-fibroblast growth factor pathway
  279. The implementation of omics technologies in cancer microbiome research
  280. Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study
  281. Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant
  282. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
  283. The use of faecal microbiota transplant as treatment for recurrent or refractoryClostridium difficileinfection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
  284. 0503 - A novel route for controlling Clostridioides difficile growth via bile acid and short chain fatty acid modulation
  285. Clostridium difficile infection and antibiotic-associated diarrhoea
  286. IDDF2018-ABS-0056 Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study
  287. PWE-052 Long term outcomes of initial IFX therapy for inflammatory pouch pathology: a multi-centre retrospective study
  288. Letter: improvements in mental health after faecal microbiota transplantation—an underexplored treatment‐related benefit?
  289. 24 - A Novel Route to Controlling Clostridioides Difficile Growth via Short Chain Fatty Acid and Bile Acid Modulation
  290. 25 - Microbiome and Metabolic Markers of Clostridium Difficile Recurrance
  291. Tu1894 - Potential Motivators and Deterents for Stool Donors: A Multicenter Study
  292. A mobile application for the management and follow-up of patients with Non-Alcoholic Fatty Liver Disease
  293. Gastrointestinal: Duodenal variceal bleeding secondary to thrombophilia‐related portal vein thrombosis
  294. P141 Infliximab therapy for inflammatory pouch pathology: a multi-centre retrospective study
  295. Posters (Abstracts 264-2239)
  296. Comparative epidemiology of Clostridium difficile infection: England and the USA
  297. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial
  298. Faecal microbiota transplant: a novel biological approach to extensively drug-resistant organism-related non-relapse mortality
  299. PWE-093 Development and validation of an automated system for assessment of liver steatosis and fibrosis in routine: histological images in patients with non-alcoholic fatty liver disease
  300. PWE-094 The severity of steatosis does not influence liver stiffness measurements in patients with non-alcoholic fatty liver disease
  301. Anticoagulation in chronic liver disease
  302. Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes
  303. National survey of practice of faecal microbiota transplantation for Clostridium difficile infection in the UK
  304. The severity of steatosis does not influence liver stiffness measurements in patients with Non-Alcoholic Fatty Liver Disease
  305. Meeting update: faecal microbiota transplantation––bench, bedside, courtroom?
  306. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance
  307. OC-040 National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom
  308. PWE-094 Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?
  309. Optimized Sample Handling Strategy for Metabolic Profiling of Human Feces
  310. Cardiology
  311. Clinical haematology and oncology
  312. Clinical sciences
  313. Dermatology
  314. Endocrinology
  315. Gastroenterology
  316. Geriatric medicine
  317. Infectious diseases and GUM
  318. Nephrology
  319. Neurology
  320. Ophthalmology
  321. Psychiatry
  322. Respiratory medicine
  323. Rheumatology
  324. Obstacles to establishing an NHS faecal transplant programme
  325. Letter: depression and the use of anti-depressants in patients with chronic liver disease or liver transplantation - authors’ reply
  326. Weight loss in a man from West Africa
  327. Global patterns of cardia and non-cardia gastric cancer incidence in 2012
  328. Case 25-2014: A Man with Ulcerative Colitis and Bloody Diarrhea
  329. Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection
  330. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation
  331. Low Incidence Of Venous Thromboembolism In Mobile Populations
  332. Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature
  333. P306 MONOCYTE OXIDATIVE BURST DEFECT PREDICTS RISK OF INFECTION IN ALCOHOLIC HEPATITIS
  334. MRCP Part 1: 400 BOFs
  335. Cardiology
  336. Clinical pharmacology, therapeutics and toxicology
  337. Clinical sciences
  338. Dermatology
  339. Endocrinology
  340. Gastroenterology
  341. Haematology and oncology
  342. Neurology
  343. Ophthalmology
  344. Psychiatry
  345. Renal medicine
  346. Respiratory medicine
  347. Rheumatology
  348. Tropical, infectious and sexually transmitted diseases
  349. Shoulder pain and dysphagia with an unexpected cause
  350. Ascites